Markets:

Overview

News

Currencies

International

Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

104.60 -1.10 (-1.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

These stocks are moving in today's after hours session ↗

November 11, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

November 10, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗

November 08, 2025

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

Via The Motley Fool

Topics Regulatory Compliance

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

November 07, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Rhythm Pharmaceuticals's Earnings: A Preview ↗

November 03, 2025

Via Benzinga

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

November 05, 2025

IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗

November 04, 2025

Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments.

Via Chartmill

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

November 04, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

October 27, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 21, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

2 Under-the-Radar Stocks That Could Soar ↗

September 21, 2025

They could ride the wave of the hottest therapeutic area in the industry.

Via The Motley Fool

Peering Into Rhythm Pharmaceuticals's Recent Short Interest ↗

September 11, 2025

Via Benzinga

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

August 27, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

August 20, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

12 Analysts Have This To Say About Rhythm Pharmaceuticals ↗

August 06, 2025

Via Benzinga

Rhythm (RYTM) Q2 Revenue Jumps 67% ↗

August 05, 2025

Via The Motley Fool

Topics Intellectual Property

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider Losses ↗

August 05, 2025

Rhythm Pharmaceuticals Q2 2025 results show revenue beat but EPS miss, causing a 5.7% pre-market drop. Regulatory progress for setmelanotide remains on track.

Via Chartmill

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

August 05, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

July 22, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Should You Invest in This Under-the-Radar Weight Loss Stock? ↗

July 21, 2025

Via The Motley Fool

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts ↗

July 18, 2025

Via Benzinga

Rhythm Pharmaceuticals CFO Sells 42,120 Shares ↗

July 18, 2025

Via The Motley Fool

Topics Regulatory Compliance

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

July 12, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

July 10, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells ↗

July 10, 2025

Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.

Via Stocktwits

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

July 09, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

July 09, 2025

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise ↗

July 09, 2025

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.